Thanks. I actually looked at them but thought it was a bit too early for me to speculate and to wait and see how their products advance. I guess I am being a bit hard on the CEO since as I recall their Neupogen product had some (potential) advantages I believe it was faster acting with neutropenia risk I could see that alone as an advantage.
Market Data 
Markets 
AI
